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Abstract
Parkinson’s disease (PD) is characterized by the loss of dopamine-producing neurons in the nigrostriatal system. Numerous
researchers in the past have attempted to track the progression of dopaminergic depletion in PD. We applied a quantitative
non-invasive PET imaging technique to follow this degeneration process in an MPTP-induced mouse model of PD. The
VMAT2 ligand
18F-DTBZ (AV-133) was used as a radioactive tracer in our imaging experiments to monitor the changes of the
dopaminergic system. Intraperitoneal administrations of MPTP (a neurotoxin) were delivered to mice at regular intervals to
induce lesions consistent with PD. Our results indicate a significant decline in the levels of striatal dopamine and its
metabolites (DOPAC and HVA) following MPTP treatment as determined by HPLC method. Images obtained by positron
emission tomography revealed uptake of
18F-DTBZ analog in the mouse striatum. However, reduction in radioligand
binding was evident in the striatum of MPTP lesioned animals as compared with the control group. Immunohistochemical
analysis further confirmed PET imaging results and indicated the progressive loss of dopaminergic neurons in treated
animals compared with the control counterparts. In conclusion, our findings suggest that MPTP induced PD in mouse model
is appropriate to follow the degeneration of dopaminergic system and that
18F-DTBZ analog is a potentially sensitive
radiotracer that can used to diagnose changes associated with PD by PET imaging modality.
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Introduction
According to the Parkinson’s disease Foundation, Parkinson’s
disease (PD) is estimated to currently affect as many as 1 million
Americans; about 50 to 60,000 Americans are diagnosed with the
disease every year. The causes of PD are still unknown; but
genetics may be a contributing factor and environmental toxins
may also play a role [1]. Investigators have used experimental
models of PD to provide insights into the mechanisms responsible
for the loss of dopaminergic neurons in PD [2]. The chemically
induced mouse model of PD using 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) has been widely used in developing
and evaluating new treatments of PD [3]. MPTP is capable of
causing clinical signs found in PD by producing a reliable and
reproducible lesion of the substantia nigra.
Non-invasive imaging studies using positron emission tomogra-
phy (PET) have been useful for monitoring the loss of dopami-
nergic neurons in PD patients and animal models with the
radiotracer 6-[
18F]-fluoro-L-DOPA (
18F-DOPA). However,
18F-
DOPA is rapidly metabolized in the periphery following in-
travenous injection, limiting its utility [4]. Thus, alternative
radiotracers have been investigated. Dihydrotetrabenazine
(DTBZ) analogs have been investigated as radiotracers for the
vesicular monoamine transporter (VMAT2) [5], expressed in the
central nervous system (CNS) [6], as well as in pancreatic beta cells
[7,8]. VMAT2 plays a role in vesicular packaging and storage of
monoamine neurotransmitters in the synapses of the brain, where
it is responsible for the movement of the monoamines (dopamine,
serotonin, and norepinephrine) from the cytosol into the vesicular
lumen [9]. VMAT2 is highly expressed in the striatum,
hypothalamus, substantia nigra, and hippocampus, with lower
levels in the cerebellum and occipital cortex [10,11]. Decreases of
VMAT2 levels have been associated with PD [12,13].
In models of PD,
3H-radiolabeled VMAT2 ligand analogs
have demonstrated loss of binding and have provided an
accurate assessment of monoamine neuronal loss. Non-invasive
imaging of CNS receptors in particular requires high specific
activity ligands. Using the positron emitter
11C, the [
11C](+)-
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numbers of dopaminergic neurons by PET [5]. However, the
relatively short half-life of
11C (20 min) and manufacturing
constraints has limited this radiotracer from widespread clinical
use. More recently, an
18F-radiolabeled DTBZ analog has been
developed, providing a radiotracer with a longer half-life
(110 min) and the potential for clinical use [6,14]. While this
analog is currently being evaluated in clinical trials [15] and in
a rat model of PD [16], the capability of this radiotracer has
not been examined using a mouse model in vivo. The purpose of
this study was to evaluate the MPTP mouse model of PD using
18F-DTBZ specific for VMAT2 to follow loss of dopaminergic
neurons. This non-invasive imaging approach can add value to
the MPTP mouse model and can assist in the development of
new treatments for PD.
Materials and Methods
Ethics Statement
All animals used in this study received humane care based on
guidelines set by the American Veterinary Association as well as in
accordance with the Guide for the Care and Use of Laboratory Animals
(Institute for Laboratory Animal Research, Washington, DC). The
experimental protocols involving live animals were reviewed and
approved by the Institutional Animal Care and Use Committee of
LSU Health Sciences Center at Shreveport (protocol P-10-028).
All efforts were made to minimize animal suffering, to reduce the
number of animals used and to utilize alternatives to in vivo
techniques, if available.
Animals
Male C57BL/6NCrl mice between 8 and 10 weeks of age were
obtained from the Jackson Laboratory (Bar Harbor, ME).
Dosing Procedure
At the start of each dosing, MPTP obtained from Sigma Aldrich
(St. Louis, MO) was reconstituted with sterile saline solution to
a concentration of 5 mg/ml. On Day 1, mice in one of three dose
groups were given four IP doses (2 hours apart) of saline, MPTP at
15 mg/kg or MPTP at 17 mg/kg and kept warm throughout the
dosing period. Each mouse was euthanized by CO2 asphyxiation
on Day 15. For each animal, the brain was harvested and the
striatum was extracted, snap frozen with liquid N2, and stored at
280uC.
Tissue Extraction
Brain sections were homogenized in 200 – 750 mL of 0.1 M
trichloroacetic acid (TCA), which contained 10
22 M sodium
acetate, 10
24 M EDTA and 10.5% methanol (pH 3.8) using
a tissue dismembrator (Fisher Scientific; Pittsburgh, PA). Samples
were spun in a microcentrifuge at 10,0006g for 20 minutes and
analyzed for biogenic monoamines and/or amino acids.
Analysis of Biogenic Amines
Samples of brain striatum were processed and analyzed at the
Neurochemistry Core lab at Vanderbilt University (Nashville TN).
Biogenic amines were determined based on a specific HPLC assay
as previously described [17] utilizing an Antec Decade II
(oxidation: 0.5) electrochemical detector operated at 33uC.
Samples of the supernatant (20 mL) were injected using a Water
717+ autosampler onto a Phenomenex Nucleosil (5 m, 100 A) C18
HPLC column (15064.60 mm). Biogenic amines were eluted with
a mobile phase consisting of 89.5% 0.1 M TCA, 10
22 M sodium
acetate, 10
24 M EDTA, and 10.5% methanol (pH 3.8). Solvent
was delivered at 0.8 mL/min using a Waters 515 HPLC pump.
Using this HPLC solvent, the following biogenic amines eluted in
the following order: noradrenaline, adrenaline, DOPAC, Dopa-
mine, 5-HIAA, HVA, 5-HT, and 3-MT. Concentrations are
expressed as nanograms per milligram of total protein.
Protein Determination
Total protein concentration of the brain extracts was de-
termined using a BCA Protein Assay Kit purchased from Pierce
Chemical Company (Rockford, IL). The frozen pellets were
allowed to thaw and reconstituted in a volume of 0.5 N HCl equal
to that previously used for tissue homogenization. A 100 mL
aliquot of this solution was combined with 2 mL of color reagent
and allowed to develop for 2 hours. A BSA standard curve was run
at the same time spanning the concentration range of 20 –
2000 mg/mL. Absorbances of standards and samples were
measured at 562 nm.
Immunohistochemical Analysis
Brain samples were stained for detection of tyrosine hydroxylase
(TH) to visualize the effect of MPTP treatment. Samples of brain
striatum were post-fixed in 10% buffered formalin (48 h, 4uC).
The fixed tissue samples were dehydrated with gradated alcohols,
cleared with xylene, and infiltrated with paraffin overnight.
Paraffin-embedded tissue samples were then cut into 5 mm-thick
sections, which were mounted on slides, deparaffinized with
xylene, and rehydrated in gradated alcohols prior to staining.
Sections were processed in a 10 mm citrate buffer for enhance-
ment of antigen retrieval. After blocking with 10% donkey serum
for 1 h, an anti-TH antibody (Sigma) was applied to the sections
for overnight incubation at 4uC. For immunofluorescence staining,
a Texas Red conjugated secondary antibody was used for
fluorescence detection. For immunohistochemistry staining,
a horseradish peroxidase conjugated secondary antibody was used
followed by 3,39 diaminobenzidine processing.
PET Imaging
The [
18F]-DTBZ radiotracer (AV133) was prepared from
aqueous [
18F]-fluoride as previously described [18]. Radiochem-
ical purity and specific activity of each synthesis were
determined by analytical HPLC. PET studies were performed
using a FLEX Triumph
TM multi-modality pre-clinical platform
(Gamma-Medica Ideas, Northridge, CA) combining three
different imaging modalities (PET, SPECT, and CT) in a single
platform. In brief, the system features 262612 mm
3 LYSO and
LGSO crystals assembled in phoswich pairs, read out by
Avalanche PhotoDiode (APD) detectors, and arranged for
a 7.5 cm transaxial field-of-view. For the imaging studies, the
mice were injected in the tail vein with 300 mCi of [
18F]-DTBZ.
After 60 minutes, the animals were anesthetized with isoflurane
and image data was acquired for 15 minutes. PET images were
reconstructed by using an iterative reconstruction technique.
The reconstructed pixel size was 0.2560.2561.175 mm, which
produces voxels of 0.07 mm
3.
CT Imaging
The purpose of the CT imaging was alignment of the PET data
for registration to a brain atlas [19]. CT images were acquired
immediately after PET imaging while the animals were still under
anesthesia. CT images were acquired with 80 kVp voltage with
optimal current, for 256 projections over 360 degrees. Recon-
structed images were either 51265126512 voxels with a voxel size
of 0.1 mm
3.
PET Imaging a Mouse Model of Parkinson’s Disease
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39041Image Analysis
Initially, one CT scan from a normal control animal was
manually reoriented so that bregma and lambda were in the
same slice plane and vertically colinear, and the intra-aural
canals were in the same plane and horizontally collinear. This
position is easily related to atlas coordinates, which commonly
reference distances from bregma, the midline, and the intra-
aural line [19]. The CT for each subsequent animal was then
registered to the first CT using the normalized mutual
information algorithm available in SPM2, a statistical image
processing utility developed for Matlab (Mathworks Inc., Natick,
MA). Finally, PET images were registered to their correspond-
ing CT and resliced in the new orientation having cubic voxel
dimensions of 0.2 mm and an origin located at the bregma.
Images were then cropped to include only the skull and brain
and intensity normalized so that the minimum voxel value was
0 and the maximum voxel value was 1. The methods used for
orienting the images were previously developed for use with
imaging PD models in rats [20]. Regions of interest for the
striatum were identified in the PET images of normal control
animals in eleven slices of the image centered on the slice
containing bregma, and individual voxels were measured within
a circle of radius 10 voxels for both left and right striatum. The
total number of cerebellar measurements for each image was
1246 voxels (178 voxels/slice). For comparison with striatum
values, regions of the cerebellum were also measured in eleven
image slices, using circular regions of 10 voxels radius. The total
number of cerebellar measurements for each image was 979
voxels (89 voxels/slice). For both striatal and cerebellar
measurements, the mean voxel values for each slice were first
determined, and then the means and standard deviations of all
slices from each image were obtained. The groups of striatal
and cerebellar slices from each animal were subsequently
compared using one-way ANOVA followed by pair-wise
Tukey’s post-hoc test. The statistics were calculated by the
GraphPad InStat version 3.2 software (GraphPad Software, Inc.,
La Jolla, CA). A P value less than 0.05 was considered
statistically significant.
Results
To implement a mouse model of PD using the neurotoxin
MPTP safely and successfully, it is critical to be consistent with
MPTP injection route, regimen and mice including strain, vendor,
gender, age, and body weight [21]. All of these factors have
a significant impact on the sensitivity and reproducibility of the
lesion caused by MPTP administration and the degree of
dopaminergic neurodegeneration. For these studies, we used
C57BL/6NCrl mice between 8 and 10 weeks of age from the
Jackson Laboratory. On Day 1, each mouse was administered four
IP doses (approximately 2 hours apart) of saline (Group 1) or
MPTP (Groups 2 and 3). Animals in Group 2 were given 15 mg/
kg doses and animals in Group 3 were given 17 mg/kg doses. The
animals in Groups 2 and 3 were noted to be hypoactive during the
first 24 hours after dosing with MPTP. These clinical signs
resolved and all animals were clinically normal throughout the rest
of the study. One Group 3 animal died acutely during the second
IP dosing procedure. Due to the circumstances of this animal’s
death, it is suspected that the death was secondary to an IP
injection error and not directly related to MPTP toxicity. Group 1
(control) animals showed no abnormal clinical signs throughout
the course of the study. No treatment-related morbidity or
mortality was reported during the study. Body weights for all
animals were obtained on days 1 and 15. Body weights were
averaged for each group and the percent of body weight gained
over the course of the study was determined for each group.
Group 1 animals gained 8.4% (2.160.7 g) of their day 1 body
weight over the course of the study, from 24.461.3 g to
26.561.6 g. Group 2 animals gained 7.2% (1.761.1 g), from
22.9 g61.3 g to 24.562.1 g, and Group 3 animals gained 6.8%
(1.660.5 g), from 23.0 g62.1 g to 24.662.4 g. The single Group
3 animal that died during dosing on Day 1 was excluded from
these calculations. Comparison of weight increase among the three
Groups showed no significant difference using a one-way ANOVA
analysis.
We initially examined the degree of dopaminergic neurodegen-
eration caused by MPTP administration by evaluating the levels of
dopamine and its main metabolites, 3,4-dihydroxyphenylacetic
acid (DOPAC) and homovanillic acid (HVA) in samples of brain
striatum from control and MPTP treated mice. The results of this
analysis are shown in Table 1 and summarized in Fig. 1. The
control Group 1 (saline only) dosing regimen was used to
determine the baseline levels for dopamine, and its two metabolites
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid
(HVA). For dose Group 2 (15 mg/kg MPTP), there was a 49.8%
decrease in dopamine content of the brain striatum relative to the
baseline levels (Group 1), from 99.2620.1 ng/mg protein to
49.8623.5 ng/mg protein. Likewise, dose Group 2 showed
a 63.9% decrease in DOPAC from 23.167.1 ng/mg protein to
8.363.3 ng/mg protein, and a 29.1% decrease in HVA from
15.963.4 ng/mg protein to 11.363.7 ng/mg protein. For dose
Group 3 (17 mg/kg) there was a 70.9% decrease in dopamine
content of the brain striatum relative to the baseline levels (Group
1), from 99.2620.1 ng/mg protein to 28.9610.8 ng/mg protein.
Likewise, dose Group 3 showed an 81.3% decrease in DOPAC
from 23.167.1 ng/mg protein to 4.461.3 ng/mg protein, and
a 47.8% decrease in HVA from 15.963.4 ng/mg protein to
8.362.1 ng/mg protein. Importantly, the measured decreases in
the biogenic amine and its metabolites are consistent with values
previously reported for a well-defined working MPTP-induced PD
mouse model [22].
As a control, we examined the effect of MPTP administration
on the catecholamines, adrenaline and noradrenaline. The results
of this analysis are shown in Table 1 and summarized in Fig. 1D.
Adrenaline levels were undetectable in tissues from any of the
animals examined, with the exception of one control animal (data
not shown). However, noradrenaline was detectable, and there
were no statistically significant differences between the noradren-
aline levels in the brain striatum for any of the groups. This lack of
change in the measured noradrenaline suggests the dissections
were performed consistently.
To further evaluate the degree of dopaminergic neurodegenera-
tion caused by MPTP administration we performed an immuno-
histochemical analysis of tyrosine hydroxylase in brain sections
from control and MPTP treated mice. Images of a sample from
a control (Group 1) animal and one from a high dose (Group 3)
animal are shown in Fig. 2. In this experiment, immunofluores-
cence visualization shows a marked decrease in the number of
dopamine neurons between the control group and the MPTP-
treated groups. The fluorescent staining pattern of tyrosine
hydroxylase shows the loss of cells in the striatum of an animal
in dose Group 3 (Fig. 2B) compared with the striatum of animal
from the control group (Fig. 2A). In addition, the staining on the
left side of each panel shows that the dopamine neurons in the
ventral tegmental area (VTA) are less affected by the MPTP than
those nigral cells. The VTA neurons are more resistant and as
such serve as a good control.
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treated mice using the VMAT2 ligand [
18F]-DTBZ (AV-133). As
shown in Fig. 3A, a clear decrease in [
18F]-DTBZ uptake can be
seen in the striatum regions of brains from mice treated with
15 mg/kg and 17 mg/kg MPTP compared with a control (un-
treated) mouse. This loss of uptake suggests that the dopaminergic
neurons in the striatum were successfully lesioned and that [
18F]-
DTBZ may be useful for imaging VMAT2 in the mouse brain. To
correlate loss of dopaminergic neurons with decreased [
18F]-
DTBZ uptake, we performed an immunohistochemical analysis of
tyrosine hydroxylase in brain sections from these mice (Fig 3B). In
these animals, the staining pattern of tyrosine hydroxylase clearly
shows the loss of cells in the striatum of treated with 15 mg/kg and
17 mg/kg MPTP compared with the striatum of the control
animal.
Quantitative analysis of the PET images from six animals is
shown in Fig. 4. In this experiment, regions of interest (ROIs) for
the striatum were identified in the PET images of two control
animals in seven slices, and individual voxel values were measured
within the ROIs for both left and right striatum. Afterwards, the
minimum voxel value was normalized to 0 and the maximum
voxel value was normalized to 1, and the mean voxel values in
each of the seven slices were obtained. The mean and standard
deviation of voxel values from all seven slices of each animal were
then determined to obtain a relative voxel value. For comparison
with striatum values, ROIs of the cerebellum were also measured
in eleven image slices using circular regions of radius 10 voxels. As
shown in Fig. 4A, the MPTP treated mice (m3 – m6) showed
significantly lower signal intensities corresponding to decreased
[
18F]-DTBZ striatum uptake, compared with either control mouse
m1 (P , 0.0001) or control mouse m2 (P , 0.0001). As a control,
the [
18F]-DTBZ uptake in the cerebellum was also examined. By
one-way ANOVA, there was no significant difference when the
control mice (m1 and m2) and the MPTP treated mice m4, m5,
and m6 were compared (P=0.639). However, m3 did show
a lower background [
18F]-DTBZ uptake (P , 0.0001) in the
cerebellum when compared with any of the other mice by pair-
wise Tukey’s post-hoc test.
Discussion
Parkinson’s disease is a progressive neurological disorder
affecting as many as one million Americans. Several animal
models have been developed to gain basic understanding about
the mechanisms involved in the onset and progression of this
progressive neurological disorder [2,22]. These include toxin, such
as MPTP, induced animal models that cause selective depletion of
dopamine producing neuronal cells [23]. With the advances in the
area of non-invasive imaging, novel radioactive ligands such as
[
11C]- and [
18F]-DTBZ have been developed that bind to the
neurotransmitter receptors with high selectivity and affinity.
Radioligands such as these have emerged as potential tools
capable of detecting the decline in dopaminergic activity in the
affected regions of the brain.
The present study demonstrates the usefulness and efficacy of
18F-DTBZ analog as a radioligand for the study of dopaminergic
loss in the MPTP induced PD mouse model. The [
18F]-DTBZ
analog is a PET tracer with a relatively longer half-life compared
with the currently available radiopharmaceuticals and shows high
affinity binding to the vesicular monoamine transporter (VMAT2),
which plays an important role in the transfer of monoamines, in
particular, neurotransmitters, from cytoplasm into synaptic
vesicles. This in turn provides a good correlation between binding
of
18F-DTBZ analog and innervation of the striatum by
dopamine-rich neurons. We substantiated the use of functional
imaging modality with classical methods employed to assess the
changes in the dopaminergic activity.
In addition to the brain, VMAT2 has been found to be
expressed in pancreatic beta cells together with insulin. This co-
localization has allowed assessment of beta cell mass by non-
invasive imaging using [
11C]- and [
18F]-DTBZ in models of
diabetes [24–26]. One limiting factor, however, for quantifying
beta cell mass has been non-specific uptake of radioligand in the
Figure 1. Changes in levels of dopamine and its main metabolites in samples of brain striatum from MPTP treated mice. The degree
of dopaminergic neurodegeneration caused by MPTP administration was evaluated by examining the levels of dopamine (A), DOPAC (B), and HVA
(C). As a control, the effect of MPTP administration on noradrenaline levels (D) was also evaluated in the same samples. Results of striatum values
from control and MPTP treated mice were analyzed by ANOVA followed by Tukey’s post-hoc test. Lowercase letters above the bars indicate the
results of that analysis; values that share any letter in common are not significantly different (P $ 0.05), and values that do not share any letter in
common are significantly different (P , 0.05).
doi:10.1371/journal.pone.0039041.g001
PET Imaging a Mouse Model of Parkinson’s Disease
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39041pancreas [27]. Recent work has suggested that sigma-1 and sigma-
2 receptors not associated with beta cells are responsible for low
affinity background binding in pancreas [28]. This and future
progress in understanding of radioligand function in pancreas as
well as VMAT2 biology should facilitate the application of [
18F]-
DTBZ for PET imaging of disease progression in patients with
diabetes.
Our findings demonstrate the considerable loss of dopamine-
producing neurons in the mouse striatum as evidenced by the
biochemical analysis of different monogenic amines in the brain
tissue samples of MPTP treated animals. A significant decrease in
the content of dopamine and its metabolic byproducts is observed
in the animals that demonstrated characteristic lesions following
treatment with MPTP neurotoxin vs. control group. In addition,
no statistically significant differences were evident in the levels of
adrenaline and noradrenaline, which served as control biomarkers
in treated and untreated groups. Our results are consistent with
previous studies characterizing dopaminergic depletion in mice
following treatment with MPTP [29–31]. In addition to these
findings, tyrosine hydroxylase levels also correlate with neuronal
degeneration in the striatum of MPTP treated mice when
compared with untreated mice [32,33].
Non-invasive imaging techniques offer several advantages
over the conventional methods, including the longitudinal
follow-up of the animals throughout the study without
euthanasia and detection of alterations in the neuronal system
in presymptomatic animals at an initial stage. We therefore,
confirmed our previous results by imaging animals using a PET
scanner. We observed reduced uptake of the
18F-radiolabeled
DTBZ analog in the mouse striatum in the treated vs. control
Table 1. Brain Striatum Levels of Dopamine, Dopamine Metabolites, and Noradrenaline.
Treatment Animal ID
Dopamine (ng/mg
protein)
DOPAC
a (ng/mg
protein) HVA
b (ng/mg protein)
Noradrenaline (ng/mg
protein)
G1-M1 86.27 26.98 17.03 2.47
G1-M2 64.44 16.22 8.81 3.86
G1-M3 88.33 19.25 12.78 2.21
G1-M4 104.71 40.13 18.55 2.78
Control G1-M5 117.46 25.29 17.96 2.44
G1-M6 100.14 22.86 16.63 3.17
G1-M7 80.66 15.75 13.13 2.54
G1-M8 134.60 23.90 20.54 2.88
G1-M9 107.06 21.85 16.25 3.17
G1-M10 108.38 18.37 17.48 4.01
Mean6S.D. 99.2620.1 23.167.1 15.964.4 2.95 60.60
G1-M11 29.42 7.08 9.73 1.44
G1-M12 9.18 1.58 3.20 3.18
G1-M13 45.28 10.36 12.47 2.12
G1-M14 63.46 12.62 17.05 3.47
15 mg/kg G1-M15 42.42 6.09 10.29 2.28
MPTP G1-M16 54.18 9.86 11.49 3.46
G1-M17 49.13 9.82 13.61 2.04
G1-M18 92.92 10.63 14.28 1.69
G1-M19 74.75 10.21 11.68 2.42
G1-M20 37.49 5.00 9.16 n.d.
c
Mean6S.D. 49.8623.5 8.363.3 11.363.7 2.4660.75
G1-M21 25.71 4.46 8.90 1.57
G1-M22 39.95 5.29 9.10 3.08
G1-M23 50.83 7.12 12.05 2.28
17 mg/kg G1-M24 22.65 3.57 6.79 1.45
MPTP G1-M25 22.37 3.98 7.14 1.23
G1-M26 26.94 3.56 7.28 2.11
G1-M27 30.91 4.44 8.60 1.53
G1-M28 13.72 2.65 4.81 3.94
G1-M30 26.83 4.67 10.10 1.37
Mean6S.D. 28.9610.8 4.461.3 8.362.1 2.0660.91
adihydroxyphenylacetic acid metabolite of dopamine.
bhomovanillic acid metabolite of dopamine.
cn.d. not determined.
doi:10.1371/journal.pone.0039041.t001
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the evolution of dopaminergic reduction in MPTP-induced PD
in monkeys [34], and with the clinical studies using different
radioactive PET imaging molecules in healthy volunteers [15]
and PD patients [35]. Furthermore, the ventral tegmental area
(VTA) was found to be weakly stained as compared with the
striatum. This difference can be attributed to the fact that
Figure 2. Immunohistochemical visualization of mouse brain striatum samples from control and MPTP treated mice. Tyrosine
hydroxylase expression was evaluated by immunofluorescence staining of a brain section from a control untreated mouse (A) or a corresponding
brain section from a mouse treated with 17 mg/kg MPTP (B).
doi:10.1371/journal.pone.0039041.g002
Figure 3. Non-invasive PET imaging of control and MPTP treated mice. A control male C57BL/6NCrl mouse and mice treated with 15 mg/kg
MPTP or 17 mg/kg MPTP were imaged by PET using [
18F]-DTBZ. (A) Shown are coronal brain slices depicting the uptake of [
18F]-DTBZ corresponding
to the anatomical localization of VMAT sites in the striatum. (B) Shown are coronal brain slices from the same animals depicting
immunohistochemical visualization of tyrosine hydroxylase activity in dopaminergic neurons.
doi:10.1371/journal.pone.0039041.g003
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MPTP-induced lesions.
A major issue with small animals such as mice is the spatial
resolution of PET imaging. In PET imaging, the emitted positron
travels some distance from the decay before annihilation with an
electron resulting in the emission of two 511 KeV gamma rays.
The random nature of this travel between the positron and gamma
ray points of origin has some impact on the lower limit of spatial
resolution obtainable from a scanner. For
18F, the travel range of
the emitted positron from the decay (Emax=0.633 MeV) is
approximately 0.6 mm in water [36]; phantom studies indicated
that 1 mm sized objects can be resolved using
18F labeled tracers
and appropriate scanner technology. Another factor is the partial
volume effect, which must be considered when performing manual
analysis (e.g., identifying the regions of interest). However, data
had the advantage of registered CT data with a resolution of
0.1 mm
3. This high-resolution CT data allowed the PET data to
be registered (and resliced) to a standard atlas to identify the brain
structures of interest. Thus, in our analysis the volume of the
sampled area was almost 10 mm
3 in each image set, which should
minimize any potential partial volume effects on the quantitative
results.
In conclusion, our approach should provide the basis to use
18F-
labeled DTBZ analogs as potent radiotracers to follow up the
process of PD involving dopamine dysfunction by positron
emission tomography. This may help in the advent of novel
diagnostic and therapeutic agents required for both the early
assessment and treatment of this neurodegenerative disorder.
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